TG Therapeutics reports five-year analysis shows BRIUMVI lowers disability progression risk vs Roche’s Ocrevus and Novartis’ Kesimpta

• TG Therapeutics announced publication of a five-year comparative analysis of Briumvi versus rival anti-CD20 drugs in relapsing multiple sclerosis.
• Results were presented as a peer-reviewed journal publication, not a future conference disclosure.
• Study suggests Briumvi could reduce long-term disability worsening risk versus ocrelizumab or ofatumumab in cross-trial comparisons.
• Analysis also indicates lower relapse activity over time versus ocrelizumab, based on adjusted comparisons rather than head-to-head testing.
• Findings were described as exploratory, highlighting potential differentiation that could support prescribing and market positioning if confirmed directly.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TG Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261012952834) on October 12, 2026, and is solely responsible for the information contained therein.